Do endocannabinoids acting via hepatic CB-1 contribute to NAFLD and hepatic insulin resistance?

George Kunos; Tony Jourdan; Joseph Tam

doi:https://doi.org/10.1172/JCI155330

Do endocannabinoids acting via hepatic CB-1 contribute to NAFLD and hepatic insulin resistance?

George Kunos, Tony Jourdan, Joseph Tam

School of Pharmacy

The Hebrew University of Jerusalem

Research output: Contribution to journal › Letter › peer-review

Original language	English
Article number	e155330
Journal	Journal of Clinical Investigation
Volume	132
Issue number	1
DOIs	https://doi.org/10.1172/JCI155330
State	Published - 4 Jan 2022

All Science Journal Classification (ASJC) codes

General Medicine

Access to Document

https://doi.org/10.1172/JCI155330

Cite this

@article{ef207145995141c6b81d6867a5819e32,

title = "Do endocannabinoids acting via hepatic CB-1 contribute to NAFLD and hepatic insulin resistance?",

author = "George Kunos and Tony Jourdan and Joseph Tam",

year = "2022",

month = jan,

day = "4",

doi = "https://doi.org/10.1172/JCI155330",

language = "الإنجليزيّة",

volume = "132",

journal = "Journal of Clinical Investigation",

issn = "0021-9738",